DRI-C21045

Research use only, not for human use.

Dri-c21045 showed concentration-dependent inhibition of NF-kB activation and all CD40L induced by B cell proliferation with IC50 of 17.1 μM and 4.5 μM.

Dri-c21045 showed concentration-dependent inhibition of NF-kB activation and all CD40L induced by B cell proliferation with IC50 of 17.1 μM and 4.5 μM, respectively. Dri-c21045 is an effective selective inhibitor of CD40-CD40L synergistic stimulator protein-protein interaction (PPI) with IC50 of 0.17 μM.

DRI-C21045 (3.2-100 μM; 18 h) concentration-dependently inhibits the CD40L-induced NF-κB activation in CD40 sensor cells.DRI-C21045 (0.6-50 μM; 48 h) blocks CD40L-induced functional activation of primary B cells.DRI-C21045 (0.4-50 μM; 48 h) inhibits CD40L-induced MHC-II upregulation in THP-1 cells.DRI-C21045 (2-100 μM; 48 h) inhibits CD40L-induced B cell proliferation.DRI-C21045 shows no signs of cytotoxicity for concentrations of up to 100 and 200 μM and has no genotoxic potential for concentrations of up to 500 μM.

DRI-C21045 (30 mg/kg; daily, s.c.; in 20% HPβCD) prolongs graft survival in a murine allogeneic skin transplant model.DRI-C21045 (20-60 mg/kg; twice daily s.c.; in 20% HPβCD) inhibits alloantigen-induced T cell expansion in the draining lymph nodes (DLNs). Animal Model:Full-thickness ear skins from BALB/c were transplanted onto the dorsal thorax of C57BL/6 Dosage:30 mg/kg Administration:Daily s.c; administered in 20% w/v hydroxypropyl-β-cyclodextrin (HPβCD) solutionResult:Caused prolongation of skin allograft survival.

——

Apoptosis

NF-κB

anandamide cellular uptake

——

——

2101765-81-3

580.61

C32H24N2O7S

>98% (HPLC)

In Vitro:?DMSO : 2 mg/mL (3.44 mM)

COC(=O)c1ccc(cc1)C(=O)Nc1ccc(cc1)-c1ccc(cc1)C(=O)Nc1cccc2cccc(c12)S(O)(=O)=O

——

(-20℃)

With Ice Pack

≥ 2 years